Animal models of polymicrobial pneumonia

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 3279-3292

  Hraiech, Sami ^a,b   Papazian, Laurent ^a,b   Rolain, Jean Marc ^a   Bregeon, Fabienne ^a,b  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b HÔPITAL NORD   (France)

Author keywords

Animal model; Co infections; Pneumonia; Polymicrobial; Route of infection

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT;

ANIMAL TESTING ALTERNATIVE; ANIMAL WELLBEING; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; BACTERIAL PNEUMONIA; BACTERIAL SUPERINFECTION; BURKHOLDERIA CENOCEPACIA; CANDIDA ALBICANS; CELLULAR IMMUNITY; CYSTIC FIBROSIS; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG RESEARCH; EXPERIMENTAL ANIMAL WELFARE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HISTOPATHOLOGY; HOST PATHOGEN INTERACTION; IMMUNOCOMPETENCE; INFECTIOUS PNEUMONIA; INFLUENZA; INFLUENZA VIRUS A H1N1; INOCULATION; LOBAR PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; LUNG ABSCESS; LUNG LESION; LUNG MYCOSIS; METAPNEUMOVIRUS INFECTION; MIXED INFECTION; MOLECULAR IMAGING; MULTIDRUG RESISTANCE; NONHUMAN; ORGANISMAL INTERACTION; PATHOPHYSIOLOGY; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS JIROVECI; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUORUM SENSING; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TRYPANOSOMA CRUZI; VIRUS PNEUMONIA; ANIMAL; ANTIFUNGAL RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECTS; HUMAN; LUNG; MICROBIOLOGY; PATHOLOGY; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCYSTIS; PNEUMONIA, VIRAL; SPECIES DIFFERENCE; TIME FACTOR; VIROLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; COINFECTION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; LUNG; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCYSTIS; PNEUMONIA, VIRAL; SPECIES SPECIFICITY; TIME FACTORS;

EID: 84936857906     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S70993     Document Type: Article

References (72)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–1757.
2. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.
3. Venditti M, Falcone M, Corrao S, Licata G, Serra P; Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150(1):19–26.
4. Maragakis LL. Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit Care Med. 2010;38(8 Suppl):S345–S351.
5. Bassetti M, Ginocchio F, Mikulska M. New treatment options against gram-negative organisms. Crit Care. 2011;15(2):215.
6. Hopewell PC. Prevention of lung infections associated with human immunodeficiency virus infection. Thorax. 1989;44(12):1038–1044.
7. Hamet M, Pavon A, Dalle F, et al. Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia. Intensive Care Med. 2012;38(8):1272–1279.
8. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev. 1982;4:25–44.
9. Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med. 2010;181(1):72–79.
10. Estenssoro E, Rios FG, Apezteguia C, et al. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med. 2010;182(1):41–48.
11. Chiche L, Forel JM, Roch A, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med. 2009;37(6):1850–1857.
12. Jaber S, Chanques G, Borry J, et al. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest. 2005;127(1):233–241.
13. Papazian L, Thomas P, Bregeon F, et al. Open-lung biopsy in patients with acute respiratory distress syndrome. Anesthesiology. 1998;88(4):935–944.
14. Bousbia S, Papazian L, Saux P, et al. Repertoire of intensive care unit pneumonia microbiota. PLoS One. 2012;7(2):e32486.
15. Mizgerd JP, Skerrett SJ. Animal models of human pneumonia. Am J Physiol Lung Cell Mol Physiol. 2008;294(3):L387–L398.
16. Johanson WG Jr, Seidenfeld JJ, Gomez P, de los SR, Coalson JJ. Bacteriologic diagnosis of nosocomial pneumonia followingprolonged mechanical ventilation. Am Rev Respir Dis. 1988;137(2):259–264.
17. Mall M, Grubb BR, Harkema JR, O’Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med. 2004;10(5):487–493.
18. Gehrig S, Duerr J, Weitnauer M, et al. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. Am J Respir Crit Care Med. 2014;189(9):1082–1092.
19. Ginsberg HS, Moldawer LL, Sehgal PB, et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A. 1991;88(5):1651–1655.
20. Kimura K, Miyazaki S, Tateda K, Matsumoto T, Tsujimoto S, Yamaguchi K. Factors affecting the course and severity of transnasally induced Staphylococcus aureus pneumonia in mice. J Med Microbiol. 1999;48(11):1005–1010.
21. Southam DS, Dolovich M, O’Byrne PM, Inman MD. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol. 2002;282(4):L833–L839.
22. LaForce FM, Boose DS. A radiolabel ratio method for measuring pulmonary clearance of intratracheal bacterial challenges. J Lab Clin Med. 1988;111(2):158–165.
23. Brain JD, Knudson DE, Sorokin SP, Davis MA. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res. 1976;11(1):13–33.
24. Hraiech S, Bregeon F, Brunel JM, et al. Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother. 2012;67(10):2452–2458.
25. Cash HA, Woods DE, McCullough B, Johanson WG Jr, Bass JA. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis. 1979;119(3):453–459.
26. Pedersen SS, Shand GH, Hansen BL, Hansen GN. Induction of experimental chronic Pseudomonas aeruginosa lung infection with P. aeruginosa entrapped in alginate microspheres. APMIS. 1990;98(3):203–211.
27. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis. 2002;186(3):341–350.
28. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962–970.
29. Shope RE. SWINE INFLUENZA: III. FILTRATION EXPERIMENTS AND ETIOLOGY. J Exp Med. 1931;54(3):373–385.
30. Seki M, Yanagihara K, Higashiyama Y, et al. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J. 2004;24(1):143–149.
31. LeVine AM, Koeningsknecht V, Stark JM. Decreased pulmonary clearance of S. pneumoniae following influenza A infection in mice. J Virol Methods. 2001;94(1–2):173–186.
32. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature. 1995;377(6548):435–438.
33. Ishizuka S, Yamaya M, Suzuki T, et al. Acid exposure stimulates the adherence of Streptococcus pneumoniae to cultured human airway epithelial cells: effects on platelet-activating factor receptor expression. Am J Respir Cell Mol Biol. 2001;24(4):459–468.
34. Kosai K, Seki M, Yanagihara K, et al. Two-dimensional gel electrophoresis analysis in simultaneous influenza pneumonia and bacterial infection in mice. Clin Exp Immunol. 2008;152(2):364–371.
35. Loffler B, Niemann S, Ehrhardt C, et al. Pathogenesis of Staphylococcus aureus necrotizing pneumonia: the role of PVL and an influenza coinfection. Expert Rev Anti Infect Ther. 2013;11(10):1041–1051.
36. Lee MH, Arrecubieta C, Martin FJ, Prince A, Borczuk AC, Lowy FD. A postinfluenza model of Staphylococcus aureus pneumonia. J Infect Dis. 2010;201(4):508–515.
37. Braun LE, Sutter DE, Eichelberger MC, et al. Co-infection of the cotton rat (Sigmodon hispidus) with Staphylococcus aureus and influenza A virus results in synergistic disease. Microb Pathog. 2007;43(5–6):208–216.
38. Lee LN, Dias P, Han D, et al. A mouse model of lethal synergism between influenza virus and Haemophilus influenzae. Am J Pathol. 2010;176(2):800–811.
39. Loving CL, Brockmeier SL, Vincent AL, Palmer MV, Sacco RE, Nicholson TL. Influenza virus coinfection with Bordetella bronchiseptica enhances bacterial colonization and host responses exacerbating pulmonary lesions. Microb Pathog. 2010;49(5):237–245.
40. Spilker T, Liwienski AA, Lipuma JJ. Identification of Bordetella spp. in respiratory specimens from individuals with cystic fibrosis. Clin Microbiol Infect. 2008;14(5):504–506.
41. Kukavica-Ibrulj I, Hamelin ME, Prince GA, et al. Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia. J Virol. 2009;83(3):1341–1349.
42. Yamasaki K, Kawanami T, Yatera K, et al. Significance of anaerobes and oral bacteria in community-acquired pneumonia. PLoS One. 2013;8(5):e63103.
43. Davis CG, Chang K, Osborne D, et al. TLR3 agonist improves survival to secondary pneumonia in a double injury model. J Surg Res. 2013;182(2):270–276.
44. Hibbing ME, Fuqua C, Parsek MR, Peterson SB. Bacterial competition: surviving and thriving in the microbial jungle. Nat Rev Microbiol. 2010;8(1):15–25.
45. Baldan R, Cigana C, Testa F, et al. Adaptation of Pseudomonas aeruginosa in Cystic Fibrosis airways influences virulence of Staphylococcus aureus in vitro and murine models of co-infection. PLoS One. 2014;9(3):e89614.
46. Bittar F, Rolain JM. Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients. Clin Microbiol Infect. 2010;16(7):809–820.
47. Bragonzi A, Farulla I, Paroni M, et al. Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response. PLoS One. 2012;7(12):e52330.
48. Vandecandelaere I, Matthijs N, Van NF, et al. Assessment of microbial diversity in biofilms recovered from endotracheal tubes using culture dependent and independent approaches. PLoS One. 2012;7(6):e38401.
49. Kannangara DW, Thadepalli H, Bach VT, Webb D. Animal model for anaerobic lung abscess. Infect Immun. 1981;31(2):592–597.
50. Kimizuka R, Kato T, Ishihara K, Okuda K. Mixed infections with Porphyromonas gingivalis and Treponema denticola cause excessive inflammatory responses in a mouse pneumonia model compared with monoinfections. Microbes Infect. 2003;5(15):1357–1362.
51. el-Ebiary M, Torres A, Fabregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med. 1997;156(2 Pt 1):583–590.
52. Rello J, Esandi ME, Diaz E, Mariscal D, Gallego M, Valles J. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest. 1998;114(1):146–149.
53. Ricard JD, Roux D. Candida pneumonia in the ICU: myth or reality? Intensive Care Med. 2009;35(9):1500–1502.
54. Azoulay E, Timsit JF, Tafflet M, et al. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest. 2006;129(1):110–117.
55. Roux D, Gaudry S, Khoy-Ear L, et al. Airway fungal colonization compromises the immune system allowing bacterial pneumonia to prevail. Crit Care Med. 2013;41(9):e191–e199.
56. Roux D, Gaudry S, Dreyfuss D, et al. Candida albicans impairs macrophage function and facilitates Pseudomonas aeruginosa pneumonia in rat. Crit Care Med. 2009;37(3):1062–1067.
57. Ader F, Jawhara S, Nseir S, et al. Short term Candida albicans colonization reduces Pseudomonas aeruginosa-related lung injury and bacterial burden in a murine model. Crit Care. 2011;15(3):R150.
58. Zielinski CE, Mele F, Aschenbrenner D, et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature. 2012;484(7395):514–518.
59. Qureshi MH, Garvy BA, Pomeroy C, Inayat MS, Oakley OR. A murine model of dual infection with cytomegalovirus and Pneumocystis carinii: effects of virus-induced immunomodulation on disease progression. Virus Res. 2005;114(1–2):35–44.
60. Oz HS, Hughes WT, Varilek GW. A rat model for combined Trypanosoma cruzi and Pneumocystis carinii infection. Microb Pathog. 2000;29(6):363–365.
61. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA. 2006;296(14):1731–1732.
62. Pene F, Zuber B, Courtine E, et al. Dendritic cells modulate lung response to Pseudomonas aeruginosa in a murine model of sepsis-induced immune dysfunction. J Immunol. 2008;181(12):8513–8520.
63. Clark CA, Thomas LK, Azghani AO. Inhibition of protein kinase C attenuates Pseudomonas aeruginosa elastase-induced epithelial barrier disruption. Am J Respir Cell Mol Biol. 2011;45(6):1263–1271.
64. Carson JL, Collier AM, Gambling TM, Knowles MR, Boucher RC. Ultrastructure of airway epithelial cell membranes among patients with cystic fibrosis. Hum Pathol. 1990;21(6):640–647.
65. Eutamene H, Theodorou V, Schmidlin F, et al. LPS-induced lung inflammation is linked to increased epithelial permeability: role of MLCK. Eur Respir J. 2005;25(5):789–796.
66. Riffo-Vasquez Y, Coates AR, Page CP, Spina D. Mycobacterium tuberculosis chaperonin 60.1 inhibits leukocyte diapedesis in a murine model of allergic lung inflammation. Am J Respir Cell Mol Biol. 2012;47(2):245–252.
67. Chen ZY, Wang YX, Yang F, Lin Y, Zhou QL, Liao YY. New researches and application progress of commonly used optical molecular imaging technology. Biomed Res Int. 2014;2014:429198.
68. Chang M, Anttonen KP, Cirillo SL, Francis KP, Cirillo JD. Real-time bioluminescence imaging of mixed mycobacterial infections. PLoS One. 2014;9(9):e108341.
69. Stanton TB. A call for antibiotic alternatives research. Trends Microbiol. 2013;21(3):111–113.
70. Ciofi Degli AM, Bernaschi P, Carletti M, et al. An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy. BMC Infect Dis. 2014;14:494.
71. Hraiech S, Hiblot J, Lafleur J, et al. Inhaled lactonase reduces Pseudomonas aeruginosa quorum sensing and mortality in rat pneumonia. PLoS One. 2014;9(10):e107125.
72. Debarbieux L, Leduc D, Maura D, et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis. 2010;201(7):1096–1104.